READ-ONLY DIGITIZATION RESULT
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.
CA Cancer J Clin · 2026 · PMID 41287969
Panel B质量警告待 EXE 对齐验证
PFS
FIGURE 3 Progression‐free survival assessed by a blinded independent review committee in (A) the HRD subgroup and (B) the HRP subgroup. Tick marks indicate the time points at which data were censored. CI indicates confidence interval; HR, hazard ratio; HRD, homologous recombination deficiency; HRP, homologous recombination proficient; NR, not reached; PFS, progression‐free survival.
算法:legacy-0.5.0引擎:enhanced-linux
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
| Curve | 序号 | X (norm) | Y (norm) | X (real) | Y (real) | X (pixel) | Y (pixel) |
|---|---|---|---|---|---|---|---|
| 3 | 1 | 0.0000 | 0.1401 | 0.0000 | 14.0097 | 86 | 207 |
| 3 | 2 | 0.0840 | 0.0773 | 4.2010 | 7.7295 | 137 | 220 |
| 3 | 3 | 0.0857 | 0.0725 | 4.2834 | 7.2464 | 138 | 221 |
| 3 | 4 | 0.0873 | 0.0725 | 4.3657 | 7.2464 | 139 | 221 |
| 3 | 5 | 0.0890 | 0.0725 | 4.4481 | 7.2464 | 140 | 221 |
| 3 | 6 | 0.0906 | 0.0725 | 4.5305 | 7.2464 | 141 | 221 |
| 3 | 7 | 0.0923 | 0.0725 | 4.6129 | 7.2464 | 142 | 221 |
| 3 | 8 | 0.0939 | 0.0725 | 4.6952 | 7.2464 | 143 | 221 |
| 3 | 9 | 0.0956 | 0.0725 | 4.7776 | 7.2464 | 144 | 221 |
| 3 | 10 | 0.0972 | 0.0725 | 4.8600 | 7.2464 | 145 | 221 |
| 3 | 11 | 0.0988 | 0.0725 | 4.9423 | 7.2464 | 146 | 221 |
| 3 | 12 | 0.1005 | 0.0725 | 5.0247 | 7.2464 | 147 | 221 |
| 3 | 13 | 0.1021 | 0.0725 | 5.1071 | 7.2464 | 148 | 221 |
| 3 | 14 | 0.1038 | 0.0725 | 5.1895 | 7.2464 | 149 | 221 |
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | quality_warning | 待验证 | 1 | 2026-07-23T17:11:30+00:00 |